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Abstract
The branched-chain amino acids (BCAA) leucine, isoleucine and valine, are essential 
amino acids that play a critical role in cellular signalling and metabolism. They 
acutely stimulate insulin secretion and activate the regulatory serine/threonine kinase 
mammalian target of rapamycin complex 1 (mTORC1), a kinase that promotes increased 
β-cell mass and function. The effects of BCAA on cellular function are dependent on 
their active transport into the mammalian cells via amino acid transporters and thus 
the expression and activity of these transporters likely influence β-cell signalling and 
function. In this report, we show that the System-L transporters are required for BCAA 
uptake into clonal β-cell lines and pancreatic islets, and that these are essential for 
signalling to mTORC1. Further investigation revealed that the System-L amino acid 
transporter 1 (LAT1) is abundantly expressed in the islets, and that knockdown of LAT1 
using siRNA inhibits mTORC1 signalling, leucine-stimulated insulin secretion and islet 
cell proliferation. In summary, we show that the LAT1 is required for regulating β-cell 
signalling and function in islets and thus may be a novel pharmacological/nutritional 
target for the treatment and prevention of type 2 diabetes.
Introduction
The branched-chain amino acids (BCAA), leucine, 
isoleucine and valine, are essential amino acids that 
play an important role in glucose homeostasis. In vitro, 
leucine stimulates insulin secretion (Newsholme et  al. 
2007) and improves insulin secretory function of 
human islets (Yang et al. 2006). Studies on the effect of 
diets containing increased BCAA or leucine on glucose 
homeostasis in vivo have been contradictory, likely due to 
differences in diet regimens and models. However, there 
is evidence that high protein diets, a source of BCAA, or 
leucine supplementation enhances insulin secretion and 
glucose clearance in healthy adults and type 2 diabetics 
(Linn et al. 1996, van Loon et al. 2003, Kalogeropoulou 
et al. 2008, Leenders & van Loon 2011). Moreover, human 
neonates fed high protein formula milk have significantly 
raised serum leucine which parallels increased C-peptide 
(Socha et al. 2011).
Branched-chain amino acids, and particularly 
leucine, are also critical for the activation of mammalian 
target of rapamycin complex 1 (mTORC1), as they 
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promote the translocation of mTORC1 to GTP-loaded 
Rheb, its upstream activator located at the lysosome 
(for review see Bar-Peled & Sabatini 2014). This process 
is dependent on a complex of proteins including RAGS 
(RAS-related GTPases), the Ragulator, v-ATPase, GATOR 
(GAP activity towards RAGS) and folliculin. Yet how 
changes in the amino acid concentration are sensed is still 
unclear. Although there is growing evidence to suggest 
that changes in the intra-lysosomal concentration play a 
significant role. Importantly, mTORC1 is a kinase whose 
hyperactivation in mice has been shown to stimulate 
both pancreatic β-cell function and mass (for reviews 
see Blandino-Rosano et  al. 2012, Xie & Herbert 2012). 
For example, β-cell-specific deletion of tuberous sclerosis 
complex-2 (Tsc2), a negative regulator of mTORC1, 
or β-cell-specific expression of constitutively active 
Rheb, a small G protein which binds to and activates 
mTORC1, results in increased β-cell mass due to increased 
proliferation and cell size (Rachdi et  al. 2008, Balcazar 
et al. 2009). Mice expressing constitutively active protein 
kinase B (PKB) in β-cells also have increased β-cell mass 
due to increased mTORC1 activity (Elghazi et al. 2007). 
Therefore, BCAA-dependent activation of mTORC1 
may be important in β-cell compensation and hence in 
protecting against the development of type 2 diabetes.
The effects of amino acids on β-cell signalling, function 
and mass are likely mediated through changes in their 
intracellular concentration. Importantly, amino acid 
transporters play an important part in determining the 
size and composition of the intracellular amino acids pool. 
There are several amino acid transporter Systems facilitating 
the transport of BCAAs, including System B0,+, System y + L, 
and System b0,+** and System-L (Hyde et  al. 2003). The 
System-L amino acid transporters (LATs) are high-affinity 
transporters of large neutral amino acids (i.e., the BCAA and 
aromatic amino acids) that are competitively inhibited by 
2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH), 
a non-metabolisable analogue of l-leucine. There are four 
members of this group called large neutral amino acid 
transporters or LATs. LAT1 and LAT2 are heterodimeric and 
are composed of a ‘light subunit’ that serves as an amino 
acid permease and a ‘heavy subunit’: glycoprotein CD98 
(cluster of differentiation 98) protein (encoded by SLC3A2) 
aka 4F2HC (4F2 cell-surface antigen heavy chain), that 
facilitates translocation of LAT to the plasma membrane 
(Verrey 2003). In contrast LAT3 and LAT4 are made up of 
a single subunit and does not require CD98 for transport 
activity (Bodoy et  al. 2005). Surprisingly, the amino acid 
transporter/s responsible for the uptake of BCAA into β-cells 
has remained largely unexplored. Moreover, their potential 
role in regulating mTORC1 activity and β-cell function 
is essentially unknown. In this report, we demonstrate 
that System-L transporters are required for signalling to 
mTORC1 in β-cells. We also show that LAT1 is the most 
predominately expressed transporter in islets and that this 
transporter plays an important role in regulating both 
β-cell signalling and function.
Materials and methods
Chemicals and media
All chemicals and media were purchased from 
Sigma-Aldrich unless otherwise stated. EBSS (Earle’s 
Balanced Salt Solution) contained 20 mM glucose, 
2 mM l-glutamine and P/S/N (50 µg/mL streptomycin, 
50 units/mL penicillin sulphate and 0.1 mg/mL Neomycin) 
and the pH was adjusted to 7.4 using NaHCO3 . MEM 
essential amino acids solution (1×) was made from a 50× 
MEM stock (Sigma M5550) and contained 0.1264 g/L 
l-Arg·HCl, 0.03128 g/L l-Cys·2HCl, 0.042 g/L l-His 
HCl·H2O, 0.0525 g/L l-Ile, 0.0524 g/L l-Leu, 0.0725 g/L 
l-Lys·HCl, 0.0151 g/L l-Met, 0.033 g/L l-Phe, 0.0476 g/L 
l-Thr, 0.0102 g/L l-Typ, 0.036 g/L l-Tyr, and 0.0468 g/L 
l-Val. MEM essential amino acid mixture (1×) without 
System-L amino acids was made using individual amino 
acids purchased from Sigma and contained 0.1264 g/L 
l-Arg·HCl, 0.03128 g/L l-Cys·2HCl, 0.042 g/L l-His 
HCl·H2O, 0.0725 g/L l-Lys·HCl, 0.0151 g/L l-Met, and 
0.0476 g/L l-Thr. DMEM minus leucine media was made 
in-house from its constituent components.
Cell culture and treatment
Rat insulinoma 1E (INS1E) cells (Merglen et al. 2004) were 
maintained in a humidified incubator (95% air, 5% CO2) 
at 37°C in RPMI-1640 medium containing 11.1 mM 
glucose, supplemented with 5% (v/v) heat inactivated 
fetal bovine serum (FBS) (Invitrogen, Thermo Scientific 
Inc, Waltham, MA, USA), 1 mM sodium pyruvate, 10 mM 
HEPES, 55 µM β-mercaptoethanol and P/S/N (50 µg/mL 
streptomycin, 50 units/mL penicillin sulphate and 
0.1 mg/mL Neomycin). Before treatments, INS1E cells 
were serum starved overnight (16 h) in CMRL-1066 
medium containing 0.5 mM l-glutamine and P/S/N. The 
cells were treated as described in the figure legends.
Pancreatic islets were isolated from Male Wistar Albino 
rats weighing 200 – 250 g and dissociated as described 
previously (Moore et  al. 2011). The dispersed cells were 
plated on a poly- d-lysine coated plates and incubated in 
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RPMI-1640 media containing 10% FBS and P/S/N. The 
cells were treated as described in the figure legends.
SDS–polyacrylamide gel electrophoresis and Western 
blot analysis
SDS–Page and Western blotting were performed as described 
previously (Moore et al. 2009) using anti-phospho Akt/PKB 
(Ser473), anti-Akt/PKB, anti-phospho S6K1(Thr389), anti-
phospho ribosomal protein S6 (Ser240/244) and anti-LC3 
A/B from Cell signalling Technologies, Beverly, MA, USA, 
and anti-ribosomal protein S6 obtained from Santa Cruz 
Biotechnology Inc, Santa Cruz, CA, USA.
Amino acid analysis
Amino acid analysis was performed essentially as described 
previously (Evans et  al. 2007). After treatments, INS1E 
or islets of Langerhans were rapidly chilled on ice, rinsed 
three times with ice-cold 1× PBS to remove extracellular 
amino acids and deproteinised by scraping with 150 µl of 
0.3 M perchloric acid. The resulting lysate was transferred 
to microcentrifuge tubes on ice, followed by incubation 
for at least 30 min. Precipitated protein was sedimented by 
centrifugation (10 min, 4°C, 14,000 g) and retained for total 
protein assay. The supernatant was filtered through a 0.45 μm 
microfilter and was immediately used for determination of 
amino acids on an Agilent 1100 high-performance liquid 
chromatograph (Agilent Technologies, Santa Clara, CA, 
USA) with Zorbax Eclipse AAA column (4.6 × 75 mm, 3.5 µm) 
at 40°C with o-phthalaldehyde/3-mercaptopropionate/ 
9-fluorenylmethylchloroformate precolumn derivatisation 
and ultraviolet and fluorimetric postcolumn detection.
RNA isolation for qRT-PCR
peqGOLD Total RNA Kit (VWR international, Germany) was 
used in RNA extraction for qRT-PCR according to manufac-
turer’s protocol. Islets of Langerhans were cultured for 2 days 
before RNA extraction. 2 µg of total RNA from each extrac-
tion were used as a template for reverse-transcription using 
the SuperScript VILO cDNA Synthesis Kit (Invitrogen). 
qRT-PCR was then performed on cDNA from 1 ng RNA using 
gene-specific primers from PrimerDesign (Southampton, 
UK): Rat LAT1 forward 5′-TTGTTCGTTCAGTAGCA-
CATTG-3′ and reverse 5′-ATTCATCGTCCGTTTGTCAGT-3′; 
Rat LAT2 forward 5′-CCAGTTCCTCTCCCCTCCT-3′ and 
reverse 5′-CAAAGTGAGTGCCATCCTGTC-3′; Rat LAT3 
forward 5′-ACACTGAAGTTTTGTCTCCGTTG-3′ and 
reverse 5′-TTGGGCAGAGTAAGTGAGGTAAA-3′; Rat LAT4 
 forward 5′-CAGAAGCGAGACAGGCAGAT-3′ and reverse 
5′-TGTAGAGGCAGATTAGGAATGAGG-3′; and 18s RNA 
primers forward 5′-GTTGGTTTTCGGAACTGAGG-3′ and 
reverse 5′-GCATCGTTTATGGTCGGAAC-3′.
Transfection of siRNAs
Rat islets of Langerhans were dispersed in a 24-well plate 
and cultured overnight in rat islet growing medium before 
transfection with Lipofectamine RNAiMAX (Invitrogen) 
in Opti-MEM medium (Invitrogen) according to the 
manufacturer’s instructions. For LAT1 knockdown, the 
cells were transfected for 72 h with 100 nM on-target plus 
siRNA (Dharmacon) against Slc7a5 (L-092749 – 01-0005) 
or 100 nM Silencer Select Pre-Designed siRNA (Invitrogen) 
against Slc7a5 (s132356).
Proliferation assay
Rat islet cell proliferation assays were performed essentially 
as described previously (Kwon et al. 2006, Xie et al. 2014). 
A total of 150 rat islets of Langerhans per treatment were 
used for proliferation assay. Islet cells were starved in 
RPMI media supplemented with 0.2% FBS and treated 
with DMEM + 16.7 mM glucose in the absence or presence 
of 0.8 mM l-leucine or 2.5 mM BCH for 48 h; 2 μCi/mL 
[3H]thymidine was added during the last 24 h. The cells 
were then collected and washed twice with 1× phosphate 
buffered saline (PBS). DNA was precipitated on ice upon the 
addition of 5% trichloroacetic acid for 30 min. The samples 
were centrifuged at 16000 × g, 4°C for 10 min and the DNA 
pellets were then solubilised by adding 0.1 N NaOH and 
incubated for 30 min at RT. [3H]thymidine incorporation 
was determined by quench-corrected scintillation counting 
using the LS6500 multi-purpose scintillation counter to 
detect DPM (disintegrations per minute) in each sample.
Leucine transport assays
The cells were preincubated for 10 min in the culture 
incubator in Leucine-free Krebs Ringer Buffer (KRB). 
l-[4,5-3H]leucine (Perkin Elmer) plus unlabelled l-leucine 
were then added to the KRB to give a final radioisotope 
concentration of 5 µCi/mL and a final total l-leucine 
concentration of 0.8 mM. BCH was also added to some 
cultures to give a final concentration of 2.5 mM. The 
cultures with 3H were then incubated in the culture 
incubator for exactly 5 min. The cells were then 
immediately placed on ice, the medium was aspirated 
off and the cells were rapidly washed 3× in ice-cold KRB. 
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0.05 M NaOH was then added to the cells and the lysates 
transferred to microcentrifuge tubes. The lysates were then 
incubated at 70ºC for 30 min. A fraction of the lysate was 
then transferred to a scintillation vial containing Ecoscint 
A scintillant and allowed to stand for at least an hour 
to allow chemiluminescence to decay before quench-
corrected scintillation counting using the LS6500 multi-
purpose scintillation counter. l-[4,5-3H]leucine transport 
rate is expressed as DPM/mg protein/5 min.
Insulin secretion assay
Following treatments, the test media were collected and 
centrifuged at 2000 g for 3 min to pellet any detached 
cells. The supernatants were collected and the insulin 
concentrations measured using a Rat Insulin Enzyme 
Immunoassay Kit (Bertin Pharma, A05105 – 96 wells) with 
rat insulin as a standard in accordance with manufacturer’s 
instructions. The absorbance was read at 414 nm on the 
NOVOstar microplate reader.
Statistical analysis
The results are expressed as means ± sem. Data were 
analysed by ANOVA, followed by Bonferroni correction 
for all pair-wise comparisons or two-tailed paired T-test 
using GraphPad Prism 6.0. Significance was assigned at 
P < 0.05.
Results and discussion
System-L transporters are critical for mTORC1 activation 
in the rodent clonal pancreatic β-cell line INS1E
The System-L amino acid transporters are widely expressed, 
and members of its family are capable of transporting 
large neutral amino acids including the BCAA. Therefore, 
we initially investigated the role of the System-L family 
of amino acid transporters in signalling to mTORC1 in 
β-cells.
Clonal rat pancreatic β-cells (INS1E cells) were treated 
with insulin to activate mTORC1, in the presence or 
absence of BCH (2-aminobicyclo-(2,2,1) heptanecarboxylic 
acid), a competitive inhibitor of System-L, or in the 
presence or absence of the System-L amino acids substrates: 
l-Leu, l-Ile, l-Val, l-Phe, l-Tyr and l-Trp (Fig.  1A). As 
anticipated, the addition of insulin led to a robust increase 
in mTORC1 activity as determined by the phosphorylation 
of its downstream target S6 kinase 1 (S6K1) on Thr389 
and a substrate of S6K1, ribosomal protein S6 (rpS6), on 
Ser240/244. Insulin also stimulated the activation of PKB, 
as assessed by its phosphorylation on Ser473 (Fig. 1A). The 
addition of BCH or the withdrawal of System-L substrates 
(i.e., l-Leu, l-Ile, l-Val, l-Phe, l-Tyr and l-Trp) significantly 
inhibited insulin-stimulated mTORC1 activation. In 
addition, BCH induced the conversion of cytosolic LC3-I 
to the lipid-bound LC3-II, which is widely used as the 
measurement of autophagic flux (Klionsky et  al. 2008), 
indicating that BCH promotes autophagy, possibly through 
its inhibition of mTORC1 (Jewell et al. 2013). Interestingly, 
BCH also inhibited insulin-stimulated phosphorylation of 
PKB. In contrast, the withdrawal of System-L amino acids 
had no significant effect on the conversion of LC3 or on 
the phosphorylation of PKB. In summary, these results 
provide good evidence that the System-L transporters 
play a critical role in signalling to mTORC1 and may also 
influence autophagy and PKB activity.
The effects of BCH and the removal of System-L 
substrates on cellular signalling are possibly mediated by 
a decrease in the intracellular concentration of BCAA. To 
investigate this, the effect of BCH or System-L AA withdrawal 
on the intracellular amino acids pool was determined by 
HPLC analysis (Fig. 1B). System-L AA withdrawal led to a 
dramatic decrease in the intracellular concentration of the 
BCAA, but had no significant effect on the intracellular 
concentration of the aromatic amino acids, likely reflecting 
their low rate of catabolism. The addition of BCH caused 
a significant decrease in the intracellular concentration of 
leucine and a trend towards a decrease in the other BCAA, 
indicating the importance of System-L transporters in the 
uptake of BCAA in β-cells. To directly investigate the role of 
System-L transporters on BCAA transport into INS1E cells, 
the effect of BCH on [3H]leucine uptake into INS1E cells was 
also determined (Fig. 1C and E). BCH caused a significant 
decrease in the uptake of [3H]leucine, demonstrating that 
System-L transporters play an important role in BCAA 
uptake into INS1E cells.
The uptake of l-leucine through System-L amino 
transporters is required for mTORC1 activation 
To determine which System-L amino acids are required 
for signalling to mTORC1, INS1E cells were depleted of 
System-L amino acids and the effect of the re-addition 
of each System-L amino acid in turn on the restoration 
of insulin signalling to mTORC1 was assessed (Fig.  2A). 
The re-addition of l-Leucine significantly restored 
insulin signalling to mTORC1, whereas the re-addition 
of l-Isoleucine, l-Valine, l-Phenylalanine, l-Tyrosine and 
l-Tryptophan had little-to-no effect on mTORC1. Thus, of 
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the System-L substrates, only l-Leucine is able to restore 
insulin signalling to mTORC1. These results confirm and 
extend previous findings in the rat insulinoma cell line 
RINm5F and isolated rat islets (Xu et al. 1998).
To investigate whether l-leucine-stimulated mTORC1 
activation was indeed dependent upon System-L 
transporters, INS1E cells depleted of leucine were incubated 
with 0.8 mM or 0.4 mM l-leucine in the presence or absence 
of 10 mM BCH (Fig. 2B). As anticipated, the re-addition 
of leucine stimulated mTORC1 activation as determined 
by the phosphorylation of S6K1 and rpS6. Surprisingly, 
leucine re-addition also inhibited the phosphorylation of 
PKB on S473 (Fig. 2B). This is possibly mediated by a well 
characterised mTORC1-dependent feedback mechanism 
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Figure 1
System-L amino acid transporters are required for signalling to mTORC1 in INS1E cells. (A) Serum starved INS1E cells were incubated for 30 min in EBSS 
(20 mM glucose, 2 mM l-glutamine) supplemented with either 1× MEM essential amino acids (EAA) (+ System-L AAs) or 1× MEM EAA minus the System-L 
amino acid substrates (− System-L AAs) in the presence or absence of 100 nM insulin ±2.5 mM BCH as indicated. Proteins were resolved by SDS–PAGE, and 
Western blotted using antisera against the proteins indicated. The results are graphically represented below showing the mean ± s.e.m for three independent 
experiments. ***P < 0.001, **P < 0.01 and *P < 0.05 compared with insulin plus System-L amino acids. (A.U. = arbitrary unit). (B) Serum starved INS1E cells were 
incubated for 30 min in EBSS (20 mM glucose, 2 mM l-glutamine) supplemented with either 1× MEM essential amino acids (EAA) and 100 nM. insulin. The 
effect of the addition of BCH (+BCH) or the withdrawal of System-L amino acids ((−)L-AAs) on intracellular amino acid concentration was determined by HPLC 
analysis. The results are mean ± s.e.m for five independent experiments. *P < 0.05 and ***P < 0.001 compared with control. (C) l-[3H]Leucine uptake (in the 
presence of 0.8 mM leucine) in the absence (−BCH) or presence (+BCH) of 2.5 mM BCH. The results presented are the mean ± s.e.m of 3 independent 
experiments. ***P < 0.001 compared with control.
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in which S6K phosphorylates insulin receptor substrate 
and inhibits insulin signalling (Harrington et  al. 2004, 
Tremblay et al. 2007). Importantly, in the presence of BCH, 
leucine-stimulated mTORC1 activation was inhibited. 
Moreover, BCH inhibited PKB and induced autophagy as 
assessed by the conversion of cytosolic LC3-I to the lipid-
bound LC3-II (Fig. 2B).
In order to define the EC50 of l-leucine to activate 
mTORC1, INS1E cells preincubated in leucine-free media 
were treated for 30 min with increasing concentrations of 
l-leucine (Fig. 2C). l-Leucine activated mTORC1 in a dose-
dependent manner with EC50s of 267 µM and 227 µM 
for S6K1 and rpS6 phosphorylation, respectively, with 
a maximum response at approximately 2 mM (Fig.  2C). 
Nifedipine, an l-type VGCC inhibitor, is unable to block 
leucine-stimulated activation of mTORC1 (Fig.  2D) and 
thus the effects of leucine on mTORC1 are not due to 
leucine-stimulated insulin secretion.
To investigate the temporal regulation of mTORC1 
activation upon leucine re-addition or withdrawal, INS1E 
cells were either depleted of leucine (Fig.  3A) or leucine 
added to leucine-starved cells (Fig. 3B) for up to 30 min, 
and changes in PKB and mTORC1 activity were determined 
(Fig. 3). The phosphorylation of S6K1 at Thr389 and rpS6 
rapidly decreased within 10 min of l-leucine withdrawal, 
and further decreased to an undetectable level by 15 min 
(Fig. 3A). The phosphorylation of PKB at Ser473 was also 
significantly decreased by 5 min of l-leucine withdrawal; 
however, PKB phosphorylation started to recover by 
15 min and returned to basal levels by 30 min (Fig. 3A). In 
addition, the conversion of LC3-I to LC3-II increased within 
5 min of l-leucine withdrawal, indicating the induction of 
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autophagy (Fig. 3A). The re-addition of leucine to leucine-
starved cells caused a rapid (within 5 – 10 min) increase in 
mTORC1 activation as determined by the phosphorylation 
of S6K1 and rpS6 (Fig. 3B). The phosphorylation of PKB at 
Ser473 also rapidly decreased but returned to basal levels 
by 30 min (Fig. 3B). In addition, the abundance of LC3-II 
rapidly decreased, indicating an inhibition of autophagy 
(Fig. 3B). Given the rapidity of these events, we investigated 
whether these changes in mTORC1 activity correlated 
with changes in the intracellular leucine concentration 
(Fig.  3C). The withdrawal of extracellular leucine for 
10 min resulted in the depletion of intracellular leucine 
whereas within 10 min of its re-addition the intracellular 
concentration of leucine returned to basal levels (Fig. 3C). 
Thus under these conditions, changes in the extracellular 
concentration of leucine are rapidly mirrored by changes 
in their intracellular concentration, which reflect the 
activation state of mTORC1.
System-L transporters are required for islet cell function 
and signalling to mTORC1
Having established the importance of System-L trans-
porters in clonal pancreatic β-cells, we wished to inves-
tigate their potential role in primary β-cells (Fig.  4). 
Therefore, islets of Langerhans were isolated from rats 
and deprived of leucine before re-addition of the Sys-
tem-L substrate l-leucine in the presence or absence of 
BCH (Fig. 4A). The re-addition of l-leucine significantly 
stimulated mTORC1, as determined by the phosphory-
lation state of S6K1 at Thr389 and rpS6 on S240/244, 
and reduced the phosphorylation of PKB at Ser473. The 
co-addition of BCH significantly inhibited leucine-stim-
ulated mTORC1 activation and also induced autoph-
agy as measured by the conversion of LC3-I to LC3-II 
(Fig. 4A). These results are similar to that observed in 
INS1E cells (Fig. 2).
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Figure 3
The temporal kinetics of leucine-dependent mTORC1 activation. INS1E cells were pre-incubated in (A) DMEM containing 0.8 mM l-leucine or  
(B) DMEM minus leucine for 1 h followed by the incubation in (A) DMEM minus leucine or (B) DMEM containing 0.8 mM l-Leucine for up to 
30 min. (A and B) Proteins were resolved by SDS–PAGE and Western blotted using antisera against the proteins indicated. The results are the 
mean ± s.e.m for at least three independent experiments. *P < 0.05, **P < 0.01 and ***P < 0.001 compared with control (i.e., 0 min time point).  
(C) Left 2 bars: INS1E cells pre-incubated in DMEM + 0.8 mM Leu for 1 h followed by incubation in DMEM minus Leu for 10 min; right 2 bars: 
pre-incubated in DMEM minus Leu for 1 h followed by incubation in DMEM + 0.8 mM Leu for 10 min. The cells were harvested and the 
intracellular concentration of leucine determined by HPLC.
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Leucine can also stimulate insulin secretion 
(Newsholme et al. 2007), therefore, in order to ascertain 
the role of System-L transporters in leucine-stimulated 
insulin secretion, rat islets of Langerhans were incubated 
in leucine-depleted media for 1 h before addition of 
leucine for 30 min in the presence or absence of BCH. 
As anticipated, leucine stimulated insulin secretion, but 
this was significantly inhibited by the presence of BCH 
(Fig. 4B), showing that leucine-dependent stimulation 
of insulin secretion is dependent upon System-L 
 transport activity.
As mTORC1 activation promotes β-cell proliferation 
(Xie et al. 2014), the role of System-L transporters on islet 
cell proliferation was also investigated. Dispersed islets 
were incubated either in the absence of l-leucine or in the 
presence of BCH, and islet cell proliferation was measured 
by the incorporation of [3H]thymidine into DNA (Fig. 4C). 
The addition of BCH or the removal of leucine significantly 
inhibited islet cell proliferation. Thus, System-L transporter 
activity is required for islet cell proliferation.
To investigate the effect of BCH or leucine withdrawal 
on the intracellular leucine concentration, HPLC amino 
acid analysis was performed (Fig.  4D). The removal of 
leucine caused the depletion in leucine, whereas its 
re-addition restored intracellular leucine concentration. 
The re-addition of leucine in the presence of BCH caused 
a significant decrease in the intracellular concentration 
of leucine, indicating that leucine uptake is mediated by 
System-L transporter (Fig. 4D). Moreover, [3H]leucine uptake 
into cells was significantly inhibited by BCH (Fig.  4E), 
providing further evidence that System-L transporters play 
a significant role in leucine transport into islets.
System-L transporter expression and function in islets of 
Langerhans
Having established that System-L transporters play a 
significant role in β-cell signalling, we wished to investigate 
which of the System-L transporters were likely responsible. 
There are four System-L amino acid: LAT1, LAT2, LAT3 
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Figure 4
System-L transporters play an important role in regulating islet signalling and function. Rat islets of Langerhans were incubated in DMEM minus 
l-leucine for 1 h before a 30-min incubation in DMEM plus or minus 0.8 mM leucine in the presence or absence of 2.5 mM BCH. (A) Proteins were 
resolved by SDS–PAGE, and Western blotted using antisera against the proteins indicated. Graphical representation of the results is shown below.  
(B) Insulin secretion assay performed by ELISA on the test medium collected at the end of above treatment. (C) Islets of Langerhans were incubated in 
RPMI supplemented with 0.2% FBS for 24 h. The medium was replaced with DMEM minus leucine or DMEM containing 0.8 mM leucine in the presence 
or absence of 2.5 mM BCH for 48 h. 2 µCi [3H]thymidine was added for the last 24 h. (D) Rat islets of Langerhans were incubated in DMEM minus 
l-leucine for 1 h before a 30-min incubation in DMEM plus or minus 0.8 mM leucine in the presence or absence of 2.5 mM BCH. Cells were harvested for 
HPLC analysis and the intracellular leucine concentration determined as described in Materials and Methods. (E) l-[4,5-3H]Leucine uptake in the presence 
of 0.8 mM leucine in either the presence (+BCH) or absence (−BCH) of 2.5 mM BCH. All results presented are the mean ± s.e.m for at least three 
independent experiments. ***P < 0.001, **P < 0.01, *P < 0.05.
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and LAT4 encoded by SLC7A5, SLC7A8, SLC43A1 and 
SLC43A2, respectively (Kanai et  al. 1998, Mastroberardino 
et al. 1998, Pineda et al. 1999, Segawa et al. 1999). In order 
to assess their relative expression in primary rat islets, 
quantitative real-time polymerase chain reaction (qRT-PCR) 
was performed (Fig.  5A). LAT1, LAT2 and LAT4 were all 
expressed in islets, although LAT1 and LAT4 were found to 
be the most abundantly expressed System-L transporters.
Both LAT1 and LAT2 are obligate heterodimers that 
require CD98 for function. Therefore, to inhibit the 
function of both LAT1 and LAT2, and not LAT3 and 
LAT4, the expression of CD98 was downregulated using 
siRNA (Fig. 5B). Knockdown of CD98 caused a significant 
decrease in the activation of mTORC1 as determined 
by the phosphorylation of S6K. There was also a trend 
towards a decrease in both PKB and rpS6 phosphorylation, 
but these changes proved statistically insignificant. Taken 
together these data would suggest that LAT1 likely plays a 
significant role in regulating mTORC1 in β-cells
LAT1 plays an important role in islet signalling to 
mTORC1 in islets of Langerhans
As LAT1 is the abundantly expressed System-L transporter 
in the islets and siRNA-mediated knockdown of CD98 
inhibits mTORC1 (Fig. 5), we focused on the role of LAT1 
in islets. Two distinct siRNAs directed against the mRNA 
encoding LAT1 (Slc7a5) (labelled LAT1-A and LAT1-B) 
were transfected into dispersed islet cells (Fig.  6). The 
efficiency of LAT1 knockdown, as determined by qRT-PCR 
 quantification, was approximately 41% and 59% using 
siRNAs LAT1-A and LAT1-B, respectively (Fig. 6C and D). 
The knockdown of LAT1 expression using both siRNAs 
had no detectable effect on cell morphology (unpublished 
observations) but caused a significant decrease in 
l-leucine-stimulated phosphorylation of S6K1 at Thr389, 
demonstrating that LAT1 is required for mTORC1 
activation (Fig.  6A and B). It also consistently caused a 
decrease in the phosphorylation of rpS6 at Ser240/244; 
however, this proved statistically insignificant. 
Interestingly, the knockdown of LAT1 using siRNA LAT1-B 
significantly inhibited PKB phosphorylation. Although 
no statistically significant change in the phosphorylation 
of PKB was detected using siRNA-A, there was a trend 
towards a decrease in PKB phosphorylation. In conclusion, 
the System-L transporter LAT1 plays an important role in 
signalling to mTORC1 and possibly PKB in islet cells.
LAT1 plays an important role in islet function and 
proliferation in islets of Langerhans
To investigate the role of LAT1 in islet function and 
proliferation, the expression of LAT1 was knockeddown in 
dispersed islets of Langerhans using siRNA. siRNA-mediated 
reduction in LAT1 expression significantly inhibited 
leucine-stimulated insulin secretion (Fig.  7A). Moreover, 
islet cell proliferation, as determined by the incorporation 
of [3H]thymidine into DNA, was also significantly inhibited 
(Fig.  7B). In conclusion, the System-L transporter LAT1 
plays an important role in islet cell proliferation and 
insulin secretion. Although a reduction in LAT1 expression 
decreases mTORC1 activation, and findings from others 
and our studies have shown that mTORC1 is required for 
β-cell proliferation (Balcazar et  al. 2009, Xie et  al. 2014), 
it is difficult to confirm whether the effects of reducing 
LAT1 expression on proliferation is indeed mediated by the 
inhibition of mTORC1. However, these effects are unlikely 
due to the potential positive effects of leucine on insulin 
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Figure 5
LAT1 is highly expressed in primary islets. (A) qPCR analysis of LAT1, LAT2, LAT3 and LAT4 expression in isolated rat islets of Langerhans expressed as fold 
change in expression of the target genes (Lat1, Lat2, Lat3 and Lat4) relative to the reference gene (18S RNA). The mean normalized expression (MNE) of 
the target genes was calculated using 2−ΔΔCT method. Expression values were multiplied by 106 for clarity of presentation. The results presented are the 
mean ± s.e.m of three independent experiments. (B) Rat islets of Langerhans were transfected with siRNAs against: CD98(Slc3a2) or scrambled siRNA as 
control. After 72 h the cells were incubated in DMEM minus Leucine for 1 h, followed by the re-addition of 0.8 mM leucine for 30 min. Proteins were 
resolved by SDS–PAGE, and Western blotted using antisera against the proteins indicated. The results are graphically represented below showing the 
mean ± s.e.m for three independent experiments. ***P < 0.001, **P < 0.01, *P < 0.05 (A.U. = arbitrary unit).
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secretion, as these experiments were carried out in nutrient-
rich media containing a high concentration of glucose.
Discussion
In this report, we provide evidence that System-L 
transporters, and in particular LAT1, play a critical role 
in β-cell signalling to mTORC1 and the maintenance of 
β-cell function and proliferation. LAT1 is highly expressed 
in rat, mouse and human islets of Langerhans ((Fig. 5) 
and (Fukushima et al. 2010, Nakada et al. 2014, Zhou et al. 
2014)) and is also highly expressed in testicular sertoli 
cells, ovarian follicular cells and proximal to proliferative 
zones in the gastrointestinal mucosa (Nakada et al. 2014). 
In addition, LAT1 is widely expressed in non-epithelial 
cells showing its highest expression in endothelial cells 
forming the blood–brain barrier in the brain, indicating 
that it is also important in transporting amino acids across 
endothelial–epithelial secretory barriers such as blood–
brain barrier (Mastroberardino et al. 1998, Verrey 2003). 
As LAT1 expression is upregulated in a range of tumours 
and is widely expressed in foetal tissue, LAT1 is thought to 
be particularly important in transporting amino acids into 
highly proliferating cells (Nakada et al. 2014, Yanagisawa 
et al. 2014). As LAT1 is an obligate amino acid exchanger, 
its activity is not only governed by extracellular amino 
acid concentration but also by the intracellular amino acid 
concentration controlled by, for example, metabolism 
and the activity and expression of other amino acid 
transporters (Meier et al. 2002, Verrey 2003). These include 
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Figure 6
LAT1 couples to mTORC1 signalling in islet cells. Rat islets of Langerhans were transfected with siRNAs against: (A) LAT1 (Slc7a5) (INVITROGEN s132356) 
(siLAT1-A) or scrambled siRNA (siScr) as control, (B) LAT1 (Slc7a5) (Dharmacon, SMART POOL on TARGET) (siLAT1-B) or scrambled siRNA (siScr) as control. 
After 72 h the cells were incubated in DMEM minus leucine for 1 h, followed by the re-addition of 0.8 mM leucine for 30 min. Proteins were resolved by 
SDS–PAGE and Western blotted using antisera against the proteins indicated. The results are graphically represented below showing the mean ± s.e.m for 
three independent experiments. ***P  <  0.001, **P  <  0.01, *P  <  0.05 (A.U. = arbitrary unit). (C and D) Quantification of LAT1 expression in dispersed rat islets 
by qPCR after 72 h of transfection with (C) LAT1 (Slc7a5) (Dharmacon, SMART POOL on TARGET) or (D) (INVITROGEN s132356). Mean ± s.e.m for three 
independent experiments. ***P  <  0.001, ** P  <  0.01, *P  <  0.05 (A.U. = arbitrary unit).
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the sodium-dependent System-A transporters, such as 
SNAT2, which transport small neutral amino acids such as 
glutamine and alanine, which act as substrates for LAT1 to 
drive the transport of BCAA and aromatic amino acid into 
the cell (Evans et al. 2007). The reported Km of LAT1 for 
BCAAs is approximately 50 – 100 µM, whereas for leucine it 
is between 18 and 62 µM (Meier et al. 2002). We show that 
the EC50 for leucine activation of mTORC1 in INS1E cells 
was approximately 200 µM, well within the physiological 
relevant range of plasma leucine concentration, which 
is between 100 and 400 µM. The difference between the 
EC50 for leucine-stimulated mTORC1 activation and the 
Km for LAT1 could be due to the factors independent 
of transport required for the activation of mTORC1, or 
they could be simply due to differences in cell systems 
and experimental conditions. Another possibility is that 
other amino acid transporters also play an important role 
in leucine uptake into β-cells, such as LAT4. LAT4 was 
also found to be highly expressed in islets (Fig 5) and this 
transporter has a Km of approximately 3 mM for leucine 
(Bodoy et al. 2005).
As the combined fasting concentration of System-L 
AA substrates is approximately 650 µM (Bergstrom et  al. 
Kidney Int. 1990), LAT1 is likely operating near saturation. 
Thus changes in the expression of LAT1 will increase 
BCAA uptake. LAT1 expression is upregulated not only by 
growth factors via the activation of mTORC1 but also by 
ER stress, probably via ATF4 (Harding et al. 2003, Liu et al. 
2004, Wang et al. 2011a, Krokowski et al. 2013, Cnop et al. 
2014). As β-cells undergo ER stress in the face of obesity 
and insulin resistance, it is possible that LAT1 expression 
is increased, which in turn leads to increased mTORC1 
activation and a compensatory increase in β-cell function 
and mass. Therefore, it is important to establish whether 
there are changes in LAT1 expression in β-cells during 
both the progression of obesity and type 2 diabetes.
Amino acid transporters have also been proposed to 
act as receptors that sense changes in the extracellular/
intracellular amino acids concentration, possibly by 
monitoring amino acid flux through the transporter, 
to transduce an intracellular signal (Hundal & Taylor 
2009). For example, SNAT2 has been proposed to act as a 
‘transceptor’ and regulate PKB activity (Evans et al. 2007, 
2008). Interestingly, BCH inhibited PKB activation. 
In addition, knockdown of LAT1 also inhibited PKB 
activity. How System-L transporters influence PKB 
activity is unknown, although it may be independent of 
the intracellular concentration of BCAA. Interestingly, 
the effects of BCH on signalling to mTORC1 and PKB 
are much stronger than that of amino acid withdrawal, 
despite the fact that amino acid withdrawal results in a 
greater effect on the intracellular level of leucine/BCAA. 
The reason for this is not entirely clear, but a possible 
explanation is that signalling to mTORC1 and PKB is 
more responsive to the l-leucine/transporter complex 
than it is to the free cytosolic l-Leu concentration 
(Hundal & Taylor 2009).
As BCAA can activate mTORC1, a kinase that 
stimulates increased pancreatic β-cell mass and function 
(for review see (Xie & Herbert 2012)), increased LAT1 
expression or activity may be anti-diabetogenic. However, 
the chronic hyperactivation of mTORC1 inhibits insulin/
growth factor signalling mediated by ribosomal protein 
S6 kinase (S6K) inhibitory phosphorylation of insulin 
receptor substrate (Um et al. 2004, 2006). Indeed, although 
β-cell-specific mTORC1 gain-of-function mutant adult 
mice have initially increased β-cell function and mass 
(Shigeyama et  al. 2008, Hamada et  al. 2009) with age, 
there is a decline in β-cell function and mass mediated 
by feedback inhibition of mTORC1 and the induction of 
autophagy (Shigeyama et al. 2008, Bartolomé et al. 2014). 
Interestingly, obese diabetic humans have increased 
circulating levels of BCAA, which is predictive of T2DM 
progression (Newgard et al. 2009, Fiehn et al. 2010, Wang 
et al. 2011b). Thus, it is plausible that elevated BCAA may 
cause chronic activation of mTORC1 in β-cells. This could 
result in a critical switch from mTORC1 stimulating β-cell 
growth to causing β-cell dysfunction, death and the onset 
of diabetes. Moreover, it has recently been reported that 
increased amino acid flux, mediated by increased AA 
transporter expression, exacerbates ER stress-induced β-cell 
death and diabetes in the Akita mouse (Krokowski et al. 
2013). Hence, although BCAA likely plays an important 
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Figure 7
LAT1 is required for islet cell function and proliferation. Dispersed rat 
islets of Langerhans were transfected with siRNAs against: (A) LAT1 
(Slc7a5) or scrambled siRNA as control. After 72 h the cells were 
incubated in DMEM minus leucine for 1 h followed by the re-addition of 
0.8 mM leucine for 30 min. An Insulin ELISA assay from on the test media 
collected after treatments. (B) Dispersed rat islets of Langerhans were 
transfected with LAT1 (Slc7a5) or scrambled siRNA as control and 
incubated for 72 h. 1 µCi/ml 3H-thymidine was added in the last 24 h.
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positive role in maintaining glucose homeostasis, chronic 
increase in circulating BCAA may be a critical determinant 
in the development of type 2 diabetes. Although this 
report focuses on the role of LAT1 in β-cell signalling and 
function, LAT2 and LAT4 were also found to be expressed 
in both clonal β-cells and islets of Langerhans and thus 
are also likely to play important roles in the β-cell.
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